JP2019533715A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2019533715A5 JP2019533715A5 JP2019525021A JP2019525021A JP2019533715A5 JP 2019533715 A5 JP2019533715 A5 JP 2019533715A5 JP 2019525021 A JP2019525021 A JP 2019525021A JP 2019525021 A JP2019525021 A JP 2019525021A JP 2019533715 A5 JP2019533715 A5 JP 2019533715A5
- Authority
- JP
- Japan
- Prior art keywords
- subject
- pharmaceutical composition
- ldl
- pcsk9
- reducing
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 238000000034 method Methods 0.000 claims 37
- 239000008194 pharmaceutical composition Substances 0.000 claims 37
- 108010028554 LDL Cholesterol Proteins 0.000 claims 32
- 239000003814 drug Substances 0.000 claims 22
- 229940124597 therapeutic agent Drugs 0.000 claims 22
- 229940122392 PCSK9 inhibitor Drugs 0.000 claims 18
- 229940121710 HMGCoA reductase inhibitor Drugs 0.000 claims 14
- 239000003795 chemical substances by application Substances 0.000 claims 14
- 101001098868 Homo sapiens Proprotein convertase subtilisin/kexin type 9 Proteins 0.000 claims 12
- 208000037260 Atherosclerotic Plaque Diseases 0.000 claims 11
- 102100038955 Proprotein convertase subtilisin/kexin type 9 Human genes 0.000 claims 10
- 206010003210 Arteriosclerosis Diseases 0.000 claims 8
- 206010003211 Arteriosclerosis coronary artery Diseases 0.000 claims 8
- 208000029078 coronary artery disease Diseases 0.000 claims 8
- 208000026758 coronary atherosclerosis Diseases 0.000 claims 8
- 230000003472 neutralizing effect Effects 0.000 claims 8
- 230000007211 cardiovascular event Effects 0.000 claims 7
- 239000002471 hydroxymethylglutaryl coenzyme A reductase inhibitor Substances 0.000 claims 4
- 208000005764 Peripheral Arterial Disease Diseases 0.000 claims 3
- 229960002027 evolocumab Drugs 0.000 claims 3
- 206010061818 Disease progression Diseases 0.000 claims 2
- 230000002411 adverse Effects 0.000 claims 2
- 230000005750 disease progression Effects 0.000 claims 2
- 230000002526 effect on cardiovascular system Effects 0.000 claims 2
- 102000053786 human PCSK9 Human genes 0.000 claims 2
- 231100000518 lethal Toxicity 0.000 claims 2
- 230000001665 lethal effect Effects 0.000 claims 2
- 208000010125 myocardial infarction Diseases 0.000 claims 2
- 230000000250 revascularization Effects 0.000 claims 2
- 230000006441 vascular event Effects 0.000 claims 2
- 206010002388 Angina unstable Diseases 0.000 claims 1
- 235000009421 Myristica fragrans Nutrition 0.000 claims 1
- 208000030831 Peripheral arterial occlusive disease Diseases 0.000 claims 1
- 208000007814 Unstable Angina Diseases 0.000 claims 1
- 201000010099 disease Diseases 0.000 claims 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 1
- 201000004332 intermediate coronary syndrome Diseases 0.000 claims 1
- 210000003141 lower extremity Anatomy 0.000 claims 1
- 239000001115 mace Substances 0.000 claims 1
- 231100001160 nonlethal Toxicity 0.000 claims 1
- 238000011084 recovery Methods 0.000 claims 1
Priority Applications (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2023019926A JP2023071715A (ja) | 2016-11-14 | 2023-02-13 | アテローム動脈硬化性心血管疾患を含むアテローム性動脈硬化症の併用療法 |
| JP2025033900A JP2025102770A (ja) | 2016-11-14 | 2025-03-04 | アテローム動脈硬化性心血管疾患を含むアテローム性動脈硬化症の併用療法 |
Applications Claiming Priority (11)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201662421685P | 2016-11-14 | 2016-11-14 | |
| US62/421,685 | 2016-11-14 | ||
| US201762471874P | 2017-03-15 | 2017-03-15 | |
| US62/471,874 | 2017-03-15 | ||
| US201762515117P | 2017-06-05 | 2017-06-05 | |
| US62/515,117 | 2017-06-05 | ||
| US201762581244P | 2017-11-03 | 2017-11-03 | |
| US62/581,244 | 2017-11-03 | ||
| US201762584600P | 2017-11-10 | 2017-11-10 | |
| US62/584,600 | 2017-11-10 | ||
| PCT/US2017/061346 WO2018089912A2 (en) | 2016-11-14 | 2017-11-13 | Combined therapies for atherosclerosis, including atherosclerotic cardiovascular disease |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023019926A Division JP2023071715A (ja) | 2016-11-14 | 2023-02-13 | アテローム動脈硬化性心血管疾患を含むアテローム性動脈硬化症の併用療法 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2019533715A JP2019533715A (ja) | 2019-11-21 |
| JP2019533715A5 true JP2019533715A5 (enExample) | 2020-12-24 |
Family
ID=60484496
Family Applications (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2019525021A Pending JP2019533715A (ja) | 2016-11-14 | 2017-11-13 | アテローム動脈硬化性心血管疾患を含むアテローム性動脈硬化症の併用療法 |
| JP2023019926A Pending JP2023071715A (ja) | 2016-11-14 | 2023-02-13 | アテローム動脈硬化性心血管疾患を含むアテローム性動脈硬化症の併用療法 |
| JP2025033900A Pending JP2025102770A (ja) | 2016-11-14 | 2025-03-04 | アテローム動脈硬化性心血管疾患を含むアテローム性動脈硬化症の併用療法 |
Family Applications After (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023019926A Pending JP2023071715A (ja) | 2016-11-14 | 2023-02-13 | アテローム動脈硬化性心血管疾患を含むアテローム性動脈硬化症の併用療法 |
| JP2025033900A Pending JP2025102770A (ja) | 2016-11-14 | 2025-03-04 | アテローム動脈硬化性心血管疾患を含むアテローム性動脈硬化症の併用療法 |
Country Status (17)
| Country | Link |
|---|---|
| US (1) | US20200368350A1 (enExample) |
| EP (1) | EP3538149A2 (enExample) |
| JP (3) | JP2019533715A (enExample) |
| KR (2) | KR20240096648A (enExample) |
| CN (1) | CN110234350A (enExample) |
| AU (2) | AU2017356219A1 (enExample) |
| BR (1) | BR112019009726A2 (enExample) |
| CA (1) | CA3043700A1 (enExample) |
| CL (2) | CL2019001304A1 (enExample) |
| CO (1) | CO2019004814A2 (enExample) |
| IL (1) | IL266579A (enExample) |
| JO (1) | JOP20190112A1 (enExample) |
| MA (1) | MA46758A (enExample) |
| MX (3) | MX2019005627A (enExample) |
| TN (1) | TN2019000156A1 (enExample) |
| WO (1) | WO2018089912A2 (enExample) |
| ZA (1) | ZA201902975B (enExample) |
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2954767A1 (en) * | 2014-07-14 | 2016-01-21 | Amgen Inc. | Crystalline antibody formulations |
| JOP20190215A1 (ar) | 2017-03-24 | 2019-09-19 | Ionis Pharmaceuticals Inc | مُعدّلات التعبير الوراثي عن pcsk9 |
| AU2019315823A1 (en) * | 2018-07-31 | 2021-04-01 | Wen Tan | New use of carbamate beta phenylethanolamine analogues for enhancing intracellular clearance of ldl cholesterol and for combining therapy with statins to enhance the efficacy and reduce adverse effects |
| WO2021012074A1 (en) * | 2019-07-19 | 2021-01-28 | Ebay Inc. | Sample delta monitoring |
| CN112656792B (zh) * | 2021-01-26 | 2022-07-05 | 首都医科大学宣武医院 | 洛美他派在制备用于治疗脑卒中引起的神经损伤药物中的用途 |
Family Cites Families (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| SG171676A1 (en) | 2006-05-11 | 2011-06-29 | Alnylam Pharmaceuticals Inc | Compositions and methods for inhibiting expression of the pcsk9 gene |
| AR070315A1 (es) | 2008-02-07 | 2010-03-31 | Merck & Co Inc | Anticuerpos 1b20 antagonistas de pcsk9 |
| AR070316A1 (es) | 2008-02-07 | 2010-03-31 | Merck & Co Inc | Antagonistas de pcsk9 (proproteina subtilisina-kexina tipo 9) |
| TWI516501B (zh) | 2008-09-12 | 2016-01-11 | 禮納特神經系統科學公司 | Ｐｃｓｋ９拮抗劑類 |
| JO3672B1 (ar) | 2008-12-15 | 2020-08-27 | Regeneron Pharma | أجسام مضادة بشرية عالية التفاعل الكيماوي بالنسبة لإنزيم سبتيليسين كنفرتيز بروبروتين / كيكسين نوع 9 (pcsk9). |
| WO2010078536A1 (en) * | 2009-01-05 | 2010-07-08 | Rxi Pharmaceuticals Corporation | Inhibition of pcsk9 through rnai |
| EP2442792A4 (en) | 2009-06-15 | 2015-12-23 | Alnylam Pharmaceuticals Inc | TESTING GENE PCSK9 LIPID-FORMULATED DSRNA |
| AR079336A1 (es) | 2009-12-11 | 2012-01-18 | Irm Llc | Antagonistas de la pro-proteina convertasa-subtilisina/quexina tipo 9 (pcsk9) |
| WO2012088313A1 (en) | 2010-12-22 | 2012-06-28 | Genentech, Inc. | Anti-pcsk9 antibodies and methods of use |
| EP2673302A1 (en) | 2011-02-11 | 2013-12-18 | Irm Llc | Pcsk9 antagonists |
| JOP20200043A1 (ar) * | 2011-05-10 | 2017-06-16 | Amgen Inc | طرق معالجة أو منع الاضطرابات المختصة بالكوليسترول |
| AR087715A1 (es) | 2011-09-16 | 2014-04-09 | Lilly Co Eli | Anticuerpos anti pcsk9 y usos de los mismos |
| US20150284473A1 (en) * | 2014-03-17 | 2015-10-08 | Laurence Bessac | Methods for reducing cardiovascular risk |
| CN113156096A (zh) * | 2015-01-09 | 2021-07-23 | 全球基因集团有限责任公司 | 用于诊断冠状动脉粥样硬化性疾病的基于血液的生物标志物 |
-
2017
- 2017-06-16 JO JOP/2019/0112A patent/JOP20190112A1/ar unknown
- 2017-11-13 BR BR112019009726A patent/BR112019009726A2/pt unknown
- 2017-11-13 WO PCT/US2017/061346 patent/WO2018089912A2/en not_active Ceased
- 2017-11-13 TN TNP/2019/000156A patent/TN2019000156A1/en unknown
- 2017-11-13 JP JP2019525021A patent/JP2019533715A/ja active Pending
- 2017-11-13 KR KR1020247018411A patent/KR20240096648A/ko active Pending
- 2017-11-13 US US16/348,653 patent/US20200368350A1/en active Pending
- 2017-11-13 CN CN201780083280.9A patent/CN110234350A/zh active Pending
- 2017-11-13 MX MX2019005627A patent/MX2019005627A/es unknown
- 2017-11-13 KR KR1020197016872A patent/KR20190085963A/ko not_active Ceased
- 2017-11-13 CA CA3043700A patent/CA3043700A1/en active Pending
- 2017-11-13 AU AU2017356219A patent/AU2017356219A1/en not_active Abandoned
- 2017-11-13 MA MA046758A patent/MA46758A/fr unknown
- 2017-11-13 EP EP17805364.1A patent/EP3538149A2/en active Pending
-
2019
- 2019-05-12 IL IL266579A patent/IL266579A/en unknown
- 2019-05-13 CO CONC2019/0004814A patent/CO2019004814A2/es unknown
- 2019-05-13 CL CL2019001304A patent/CL2019001304A1/es unknown
- 2019-05-13 ZA ZA2019/02975A patent/ZA201902975B/en unknown
- 2019-05-14 MX MX2025002106A patent/MX2025002106A/es unknown
- 2019-05-14 MX MX2024000805A patent/MX2024000805A/es unknown
-
2020
- 2020-11-18 CL CL2020002993A patent/CL2020002993A1/es unknown
-
2023
- 2023-02-13 JP JP2023019926A patent/JP2023071715A/ja active Pending
-
2024
- 2024-12-06 AU AU2024278180A patent/AU2024278180A1/en active Pending
-
2025
- 2025-03-04 JP JP2025033900A patent/JP2025102770A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2019533715A5 (enExample) | ||
| Keene et al. | Effect on cardiovascular risk of high density lipoprotein targeted drug treatments niacin, fibrates, and CETP inhibitors: meta-analysis of randomised controlled trials including 117 411 patients | |
| Ong et al. | An evidence-based update on nonsteroidal anti-inflammatory drugs | |
| IL277127B1 (en) | Using pcsk9 tracking to reduce cardiovascular risk | |
| Abraham et al. | Optimal management of digital ulcers in systemic sclerosis | |
| NO20073456L (no) | Omega-3 fettsyrer og dyslipidemisk middel for lipidbehandling | |
| RU2013121788A (ru) | Ингибиторы репликации вич | |
| MX393855B (es) | Terapia de combinación que comprende un inhibidor de raf y trametinib | |
| IL300151A (en) | Combinations for the treatment of cancer | |
| JP2017506626A5 (enExample) | ||
| HRP20250797T1 (hr) | Postupci za liječenje pacijenata s obiteljskom hiperkolesterolemijom | |
| JP2017528427A5 (enExample) | ||
| JP2015518897A5 (enExample) | ||
| Simon et al. | Treatment of hypertensive and hypercholesterolaemic patients with the triple fixed combination of atorvastatin, perindopril and amlodipine: the results of the CORAL study | |
| KR20160043117A (ko) | 가속화된 경화반 퇴행을 위한 조성물 및 치료방법 | |
| Bertrand et al. | Triple combination therapy for global cardiovascular risk: atorvastatin, perindopril, and amlodipine | |
| Mostaza et al. | Safety and efficacy of a cardiovascular polypill in people at high and very high risk without a previous cardiovascular event: the international VULCANO randomised clinical trial | |
| JP4839309B2 (ja) | 血栓症治療剤 | |
| US9713608B2 (en) | Method for topically treating actinic keratosis on the trunk (except chest) or extremities with ingenol 3-(3,5-diethylisoxazole-4-carboxylate) | |
| Amuchastegui et al. | Disulfiram--alcohol reaction mimicking an acute coronary syndrome. | |
| Teixeira | Scientific basis of the homeopathic healing principle in modern pharmacology | |
| JP2018516931A5 (enExample) | ||
| WO2008121461A3 (en) | Vaccine for activating helper function of cd8+ tcells | |
| Polska | Safety and tolerability of the use of atorvastatin 40 mg in common daily practice in short-term observation in 3,227 patients | |
| Hadjibabaie et al. | Comparative efficacy and safety of atorvastatin, simvastatin and lovastatin in the management of dyslipidemic Type 2 diabetic patients |